MXPA06011830A - Composicion farmaceutica que comprende una sal de mirtazapina. - Google Patents
Composicion farmaceutica que comprende una sal de mirtazapina.Info
- Publication number
- MXPA06011830A MXPA06011830A MXPA06011830A MXPA06011830A MXPA06011830A MX PA06011830 A MXPA06011830 A MX PA06011830A MX PA06011830 A MXPA06011830 A MX PA06011830A MX PA06011830 A MXPA06011830 A MX PA06011830A MX PA06011830 A MXPA06011830 A MX PA06011830A
- Authority
- MX
- Mexico
- Prior art keywords
- mirtazapine
- salt
- acid
- sublimation
- tablets
- Prior art date
Links
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 title claims abstract description 38
- 150000003839 salts Chemical class 0.000 title claims abstract description 38
- 229960001785 mirtazapine Drugs 0.000 title claims abstract description 33
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 21
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims abstract description 22
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims abstract description 17
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims abstract description 15
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims abstract description 15
- 239000011976 maleic acid Substances 0.000 claims abstract description 15
- RONZAEMNMFQXRA-INIZCTEOSA-N LSM-5894 Chemical compound C1C2=CC=CN=C2N2CCN(C)C[C@H]2C2=CC=CC=C21 RONZAEMNMFQXRA-INIZCTEOSA-N 0.000 claims abstract description 14
- 239000007787 solid Substances 0.000 claims abstract description 13
- 238000004519 manufacturing process Methods 0.000 claims abstract description 9
- 239000001530 fumaric acid Substances 0.000 claims abstract description 7
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 claims abstract description 5
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 8
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 5
- RONZAEMNMFQXRA-MRXNPFEDSA-N esmirtazapine Chemical class C1C2=CC=CN=C2N2CCN(C)C[C@@H]2C2=CC=CC=C21 RONZAEMNMFQXRA-MRXNPFEDSA-N 0.000 description 59
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 34
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- 239000000243 solution Substances 0.000 description 23
- 238000000859 sublimation Methods 0.000 description 23
- 230000008022 sublimation Effects 0.000 description 23
- 239000000203 mixture Substances 0.000 description 20
- 239000013078 crystal Substances 0.000 description 18
- 150000001875 compounds Chemical class 0.000 description 16
- 238000002425 crystallisation Methods 0.000 description 16
- 230000008025 crystallization Effects 0.000 description 16
- 238000012360 testing method Methods 0.000 description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- -1 pyrido [2, 1-a] pyrido [2,3-c] [2] benzazepine Chemical compound 0.000 description 10
- 239000002585 base Substances 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 238000001914 filtration Methods 0.000 description 7
- 239000012458 free base Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 6
- 239000007857 degradation product Substances 0.000 description 6
- 150000002689 maleic acids Chemical class 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 5
- 238000000634 powder X-ray diffraction Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 210000000078 claw Anatomy 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000002178 crystalline material Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 229940126534 drug product Drugs 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000012080 ambient air Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000000110 cooling liquid Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- MYXKPFMQWULLOH-UHFFFAOYSA-M tetramethylazanium;hydroxide;pentahydrate Chemical compound O.O.O.O.O.[OH-].C[N+](C)(C)C MYXKPFMQWULLOH-UHFFFAOYSA-M 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- NWXITVQAKIFZLZ-UHFFFAOYSA-N 191546-96-0 Chemical compound C1C2=CC=CN=C2N2CCN(C)C(=O)C2C2=CC=CC=C21 NWXITVQAKIFZLZ-UHFFFAOYSA-N 0.000 description 1
- RZDFSDWHGNDESU-UHFFFAOYSA-N 191546-97-1 Chemical compound O=C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RZDFSDWHGNDESU-UHFFFAOYSA-N 0.000 description 1
- KMGUEILFFWDGFV-UHFFFAOYSA-N 2-benzoyl-2-benzoyloxy-3-hydroxybutanedioic acid Chemical compound C=1C=CC=CC=1C(=O)C(C(C(O)=O)O)(C(O)=O)OC(=O)C1=CC=CC=C1 KMGUEILFFWDGFV-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GAFCUVMEBFTFQJ-UHFFFAOYSA-N Mirtazapine-N-oxide Chemical compound C1C2=CC=CN=C2N2CCN(C)(=O)CC2C2=CC=CC=C21 GAFCUVMEBFTFQJ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04101664 | 2004-04-21 | ||
| PCT/EP2005/051714 WO2005102352A1 (en) | 2004-04-21 | 2005-04-19 | Pharmaceutical composition comprising a salt of mirtazapine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA06011830A true MXPA06011830A (es) | 2007-03-23 |
Family
ID=34928990
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA06011830A MXPA06011830A (es) | 2004-04-21 | 2005-04-19 | Composicion farmaceutica que comprende una sal de mirtazapina. |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US20070111993A1 (enExample) |
| EP (1) | EP1729777B1 (enExample) |
| JP (2) | JP5260959B2 (enExample) |
| CN (2) | CN1942191B (enExample) |
| AR (1) | AR049028A1 (enExample) |
| AT (1) | ATE424210T1 (enExample) |
| AU (1) | AU2005235383B2 (enExample) |
| BR (1) | BRPI0509953A (enExample) |
| CA (1) | CA2561281C (enExample) |
| CY (1) | CY1109018T1 (enExample) |
| DE (1) | DE602005013066D1 (enExample) |
| DK (1) | DK1729777T3 (enExample) |
| EC (1) | ECSP066938A (enExample) |
| ES (1) | ES2321961T3 (enExample) |
| HR (1) | HRP20090190T1 (enExample) |
| IL (1) | IL178201A (enExample) |
| LV (1) | LV13556B (enExample) |
| MX (1) | MXPA06011830A (enExample) |
| MY (1) | MY144899A (enExample) |
| NO (1) | NO20065077L (enExample) |
| NZ (1) | NZ550052A (enExample) |
| PE (1) | PE20060400A1 (enExample) |
| PL (1) | PL1729777T3 (enExample) |
| PT (1) | PT1729777E (enExample) |
| RS (1) | RS50764B (enExample) |
| RU (1) | RU2375362C2 (enExample) |
| SI (1) | SI1729777T1 (enExample) |
| TW (1) | TW200538100A (enExample) |
| UA (1) | UA89773C2 (enExample) |
| WO (1) | WO2005102352A1 (enExample) |
| ZA (1) | ZA200608305B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA83666C2 (ru) * | 2003-07-10 | 2008-08-11 | Н.В. Органон | Способ получения энантиомерно чистого миртазапина |
| EP1792618A1 (en) * | 2005-11-30 | 2007-06-06 | Rainer Freynhagen | R-mirtazapine for the treatment of pain |
| TW200808804A (en) * | 2006-05-22 | 2008-02-16 | Organon Nv | Mirtazapine for the treatment of neuropathic pain |
| CN104095824B (zh) * | 2013-04-09 | 2016-08-31 | 上海信谊万象药业股份有限公司 | 一种米氮平缓释片及其制备方法 |
| JP6876003B2 (ja) | 2015-02-27 | 2021-05-26 | デクラ リミテッド | イヌ及びネコにおける、食欲の刺激、体重減少の管理、及び拒食症の処置 |
| CN111053735A (zh) * | 2020-02-25 | 2020-04-24 | 上海阶平医院管理有限公司 | 一种治疗失眠的冷敷凝胶 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL189199C (nl) * | 1975-04-05 | 1993-02-01 | Akzo Nv | Werkwijze ter bereiding van farmaceutische preparaten met werking op het centraal zenuwstelsel op basis van benz(aryl)azepinederivaten, de verkregen gevormde farmaceutische preparaten, alsmede werkwijze ter bereiding van de toe te passen benz(aryl)azepinederivaten. |
| US4193828A (en) * | 1976-07-27 | 1980-03-18 | Fiber Materials, Inc. | Method of forming carbon composites |
| US4515792A (en) * | 1982-09-30 | 1985-05-07 | Ciba-Geigy Corporation | Tetracyclic heterocycles and antidepressant compositions thereof |
| IL121076A (en) * | 1996-06-19 | 2000-10-31 | Akzo Nobel Nv | Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors |
| EP0813873B1 (en) * | 1996-06-19 | 2002-02-13 | Akzo Nobel N.V. | Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors |
| ES2212550T3 (es) * | 1998-04-02 | 2004-07-16 | Akzo Nobel N.V. | Solucion oral liquida que comprende el antidepresor mirtazapina. |
| WO2001000196A2 (en) * | 1999-06-25 | 2001-01-04 | University Of South Florida | Mirtazapine for weight gain in wasting diseases |
| US6281207B1 (en) * | 1999-09-15 | 2001-08-28 | Reed Richter | Treatment of movement disorders by administration of mirtazapine |
| WO2001042239A1 (en) * | 1999-12-13 | 2001-06-14 | Sumika Fine Chemicals Co., Ltd. | Process for the preparation of a pyridinemethanol compound |
| HK1047547B (en) * | 2000-04-05 | 2003-10-10 | Akzo Nobel N.V. | Drug combination for the treatment of headache comprising mirtazapine and paracetamol or a non-steroidal anti-inflammatory drug |
-
2005
- 2005-04-12 TW TW094111559A patent/TW200538100A/zh unknown
- 2005-04-19 BR BRPI0509953-6A patent/BRPI0509953A/pt not_active IP Right Cessation
- 2005-04-19 RS RSP-2009/0164A patent/RS50764B/sr unknown
- 2005-04-19 WO PCT/EP2005/051714 patent/WO2005102352A1/en not_active Ceased
- 2005-04-19 UA UAA200610312A patent/UA89773C2/ru unknown
- 2005-04-19 EP EP05740221A patent/EP1729777B1/en not_active Expired - Lifetime
- 2005-04-19 CN CN2005800116628A patent/CN1942191B/zh not_active Expired - Fee Related
- 2005-04-19 DE DE602005013066T patent/DE602005013066D1/de not_active Expired - Lifetime
- 2005-04-19 PT PT05740221T patent/PT1729777E/pt unknown
- 2005-04-19 NZ NZ550052A patent/NZ550052A/en unknown
- 2005-04-19 CA CA2561281A patent/CA2561281C/en not_active Expired - Fee Related
- 2005-04-19 HR HR20090190T patent/HRP20090190T1/xx unknown
- 2005-04-19 PL PL05740221T patent/PL1729777T3/pl unknown
- 2005-04-19 RU RU2006140988/04A patent/RU2375362C2/ru not_active IP Right Cessation
- 2005-04-19 ES ES05740221T patent/ES2321961T3/es not_active Expired - Lifetime
- 2005-04-19 US US11/547,152 patent/US20070111993A1/en not_active Abandoned
- 2005-04-19 MX MXPA06011830A patent/MXPA06011830A/es not_active IP Right Cessation
- 2005-04-19 SI SI200530673T patent/SI1729777T1/sl unknown
- 2005-04-19 AT AT05740221T patent/ATE424210T1/de active
- 2005-04-19 MY MYPI20051731A patent/MY144899A/en unknown
- 2005-04-19 CN CN201010174000A patent/CN101824035A/zh active Pending
- 2005-04-19 JP JP2007508904A patent/JP5260959B2/ja not_active Expired - Fee Related
- 2005-04-19 AU AU2005235383A patent/AU2005235383B2/en not_active Expired
- 2005-04-19 DK DK05740221T patent/DK1729777T3/da active
- 2005-04-20 AR ARP050101549A patent/AR049028A1/es unknown
- 2005-04-20 PE PE2005000439A patent/PE20060400A1/es not_active Application Discontinuation
-
2006
- 2006-09-20 IL IL178201A patent/IL178201A/en not_active IP Right Cessation
- 2006-10-05 ZA ZA200608305A patent/ZA200608305B/xx unknown
- 2006-10-19 EC EC2006006938A patent/ECSP066938A/es unknown
- 2006-11-03 NO NO20065077A patent/NO20065077L/no not_active Application Discontinuation
- 2006-11-21 LV LVP-06-130A patent/LV13556B/lv unknown
-
2009
- 2009-05-05 CY CY20091100481T patent/CY1109018T1/el unknown
-
2013
- 2013-03-08 JP JP2013046645A patent/JP2013136626A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6211072B2 (ja) | ダサチニブと、選択された共結晶形成剤とを含んでなる多成分結晶 | |
| JP5043825B2 (ja) | Ｄｐｐ−ｉｖ阻害剤の新規な塩及び多形 | |
| MXPA06006696A (es) | (s)-2-n-propilamino-5-hidroxitetralina como un agonista-d3. | |
| KR20190022895A (ko) | [3-(1-(1h-이미다졸-4-일)에틸)-2-메틸페닐] 메탄올의 에스테르 프로드러그 | |
| JP2013136626A (ja) | ミルタザピンの塩を含む医薬組成物 | |
| AU2014295144B2 (en) | Salts of Dasatinib in crystalline form | |
| HU227755B1 (en) | Crystalline forms of 33-epichloro-33-desoxyascomycin, process for their preparation and pharmaceutical compositions containing them | |
| EP0826684B1 (en) | Piperidine derivatives | |
| JPWO1996030367A1 (ja) | ピペリジン誘導体 | |
| CA2467555A1 (en) | Preparation of pharmaceutical salts of 4 ( (z) - (4-bromophenyl) (ethoxyimino) methyl)-1'-( (2,4-dimethyl-1-oxido-3-pyridinyl) carbonyl) -4'-me thyl-1,4' bipiperidine as ccr5-antagonists for the treatment of aids and related hiv infections | |
| CA2468525A1 (en) | Process for the preparation of compositions having an increased amount of pharmaceutically active salts of rotamers of 4-[4-[(1r)-[4-(trifluoromethyl)phenyl]-2-methoxyethyl]-(3s)-methyl-1-piperazinyl]-4-methyl-1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl] | |
| JP3588363B2 (ja) | キノキサリンジオン類 | |
| WO2019134455A1 (zh) | Acalabrutinib的新晶型及其制备方法和用途 | |
| RU2352563C2 (ru) | Атропоизомеры производных 3-замещенного-4-арилхинолин-2-она | |
| DK169622B1 (da) | Trans-(+)-stereoisomere af pyrimido[4,5-g]quinolin-derivater eller farmaceutisk acceptable syreadditionssalte deraf samt farmaceutiske formuleringer indeholdende sådanne forbindelser | |
| KR20070022037A (ko) | 미르타자핀의 염을 포함하는 약학 조성물 | |
| WO2012123958A1 (en) | Highly pure salts of clopidogrel free of genotoxic impurities | |
| KR20000075717A (ko) | 퀴녹살린디온 | |
| JP2002030080A (ja) | （３ｓ−トランス）−２−［３，４−ジヒドロ−４−ヒドロキシ−３−（フェニルメチル）−２ｈ−１−ベンゾピラン−７−イル］−４−（トリフルオロメチル）−安息香酸の新規結晶形体 | |
| TW201713647A (zh) | １－（４－（２－（（１－（３，４－二氟苯基）－１ｈ－吡唑－３－基）甲氧基）乙基）呱嗪－１－基）乙酮鹽 | |
| TW201609788A (zh) | 類固醇樣化合物之多晶型形式以及其製備方法及用途 | |
| JP2000507562A (ja) | ジメチル―置換シクロヘキサンジエン誘導体 | |
| WO2019011336A1 (zh) | Qaw-039的晶型及其制备方法和用途 | |
| CZ9903052A3 (cs) | Chinoxalindiony, způsoby a meziprodukty pro jejich výrobu, jejich použití, farmaceutické přípravky na jejich bázi a způsoby léčení |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration | ||
| MM | Annulment or lapse due to non-payment of fees |